Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2017; 9(10): 407-415
Published online Oct 15, 2017. doi: 10.4251/wjgo.v9.i10.407
Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer
Manju D Chandrasegaram, Anthony J Gill, Jas Samra, Tim Price, John Chen, Jonathan Fawcett, Neil D Merrett
Manju D Chandrasegaram, the Prince Charles Hospital, Brisbane, Queensland 4032, Australia
Manju D Chandrasegaram, Jonathan Fawcett, School of Medicine, University of Queensland, Queensland 4006, Australia
Anthony J Gill, Jas Samra, Sydney Medical School, University of Sydney, New South Wales 2006, Australia
Anthony J Gill, Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
Jas Samra, Department of Surgery, Royal North Shore Hospital, Sydney, New South Wales 2065, Australia
Tim Price, Queen Elizabeth Hospital, Adelaide, South Australia 5011, Australia
Tim Price, University of Adelaide, South Australia 5005, Australia
John Chen, Flinders Medical Centre, Adelaide, South Australia 5042, Australia
John Chen, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia
Jonathan Fawcett, Princess Alexandra Hospital, Brisbane, Queensland 4102, Australia
Neil D Merrett, Department of Upper GI Surgery, Bankstown Hospital, Sydney, New South Wales 2200, Australia
Neil D Merrett, Discipline of Surgery, Western Sydney University, Sydney, New South Wales 2560, Australia
Author contributions: All the authors made substantial contributions to (1) conception, design, analysis and interpretation of data; (2) making critical revisions related to important intellectual content of the manuscript; and (3) final approval of the version of the article to be published.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Dr. Manju D Chandrasegaram, the Prince Charles Hospital, Rode Road, Chermside, Brisbane, Queensland 4032, Australia.
Telephone: +61-7-31930800 Fax: +61-7-33196761
Received: January 31, 2017
Peer-review started: February 8, 2017
First decision: May 8, 2017
Revised: June 26, 2017
Accepted: August 16, 2017
Article in press: August 17, 2017
Published online: October 15, 2017
Core Tip

Core tip: Periampullary cancers include pancreatic, ampullary, bile duct and duodenal cancers. Pancreatic cancer is the most common cancer resected with a pancreaticoduodenectomy followed by ampullary, bile duct and duodenal cancer. Patients with resected duodenal and ampullary cancers have better prognosis compared to pancreatic cancer. Ampullary cancers can be subdivided into intestinal or pancreatobiliary subtype cancers with histomolecular staining. Histomolecular profiling is superior to anatomic location in prognosticating survival. Ampullary cancers of intestinal subtype and duodenal cancers are similar in their intestinal origin and form a logical clinical and therapeutic subgroup. They respond to 5-FU based chemotherapeutic regimens such as capecitabine-oxaliplatin.